Last reviewed · How we verify
Activated Prothrombin Complex Concentrate
Activated Prothrombin Complex Concentrate works by replacing clotting factors to help the blood to clot.
Activated Prothrombin Complex Concentrate works by replacing clotting factors to help the blood to clot. Used for Treatment of bleeding episodes in patients with hemophilia A or B, Treatment of bleeding in patients with acquired hemophilia A.
At a glance
| Generic name | Activated Prothrombin Complex Concentrate |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Coagulation factor replacement therapy |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 2 |
Mechanism of action
It is used to treat bleeding episodes in patients with hemophilia A or B, and in patients with acquired hemophilia A. Activated Prothrombin Complex Concentrate contains a mixture of clotting factors that are necessary for blood to clot.
Approved indications
- Treatment of bleeding episodes in patients with hemophilia A or B
- Treatment of bleeding in patients with acquired hemophilia A
Common side effects
- Hypersensitivity reactions
- Thromboembolic events
Key clinical trials
- An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care Treatment
- SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis (PHASE3)
- A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery (PHASE3)
- Comparative Outcomes of PCC and Recombinant Activated Factor VIIa in Trauma-Associated Massive Transfusion
- Treatment of Hemophilia A Patients With FVIII Inhibitors
- Factor IX as Adjunctive Therapy to Emicizumab (EMIX) (EARLY_PHASE1)
- Transgender Estradiol Affirming Therapy (PHASE2)
- CPP Versus PFC to Correct Coagulation Disorders in Adult Neurosurgical Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |